Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ayala Pharmaceuticals Inc ADXS

Healthcare Biotechnology
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia... see more

Recent & Breaking News (PINL:ADXS)

Advaxis Announces Receipt of Second Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies

GlobeNewswire April 26, 2021

Advaxis, Inc. Announces $20 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire April 12, 2021

Advaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR) 2021 Annual Meeting

GlobeNewswire April 10, 2021

Advaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase 1 Study of ADXS-504 for the Treatment of Early Prostate Cancer

GlobeNewswire April 5, 2021

Advaxis to Present Corporate Overview at the Benzinga Biotech Small Cap Conference

GlobeNewswire March 23, 2021

Advaxis Reports First Quarter Ended January 31, 2021 Financial Results and Provides a Business Update

GlobeNewswire March 16, 2021

Advaxis to Present at the American Association for Cancer Research (AACR) 2021 Annual Meeting

GlobeNewswire March 12, 2021

Advaxis Reports Fiscal Year 2020 Financial Results and Provides a Business Update

GlobeNewswire January 25, 2021

Advaxis Announces Receipt of Funding Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies

GlobeNewswire January 19, 2021

Advaxis Announces Listing Transfer to Nasdaq Capital Market and Additional 180-day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

GlobeNewswire December 22, 2020

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Advaxis, Inc.- ADXS

Newsfile December 16, 2020

INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Advaxis, Inc. for Potential Breach of Fiduciary Duty Claims

ACCESSWIRE IA December 16, 2020

Advaxis, Inc. Announces Closing of $9.2 Million Public Offering

GlobeNewswire November 27, 2020

Advaxis, Inc. Announces Pricing of $8 Million Public Offering

GlobeNewswire November 24, 2020

Advaxis, Inc. Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock

GlobeNewswire November 23, 2020

Advaxis Presents Updated Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire November 9, 2020

Advaxis' ADXS-503 (HOT Lung) Demonstrates Pronounced and Sustained Tumor Control in Ongoing Phase 1/2 Lung Cancer Trial

GlobeNewswire October 26, 2020

Advaxis to Present Data from Ongoing ADXS-503 Phase 1/2 Clinical Trial at SITC 2020

GlobeNewswire October 15, 2020

Advaxis, Inc. Adopts Limited Duration Stockholder Rights Plan

GlobeNewswire September 29, 2020

Advaxis Announces FDA Clearance of New IND for ADXS-504 for Treatment of Prostate Cancer

GlobeNewswire September 24, 2020